Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Neurol.

Sec. Neuroepidemiology

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1674245

This article is part of the Research TopicLeveraging Big Data Mining to Advance Neurological ResearchView all 5 articles

Efficacy and Safety of Bloodletting Therapy for Acute Herpes Zoster: A Systematic Review and Meta-Analysis

Provisionally accepted
Danhui  WuDanhui Wu1*Yanbin  JiangYanbin Jiang1Qiqi  WuQiqi Wu2Yibo  JinYibo Jin3Chenda  WangChenda Wang1Lihua  GuanLihua Guan1Wei  ShaoWei Shao1*
  • 1Quzhou Hospital of Traditional Chinese Medicine, Quzhou, China
  • 2Wenzhou Central Hospital, Wenzhou, China
  • 3Zhejiang Chinese Medical University, Hangzhou, China

The final, formatted version of the article will be published soon.

Background: The high incidence of acute herpes zoster (HZ) and limitations of conventional therapies in pain control necessitate exploration of complementary approaches. Bloodletting therapy (BLT), a traditional intervention with potential analgesic and immunomodulatory effects, has been increasingly applied in China, yet its efficacy remains controversial due to inconsistent clinical evidence. Methods: A systematic search was conducted in databases including PubMed, Embase, the Cochrane Library, MEDLINE, CNKI, the Wan Fang database, the Chinese clinical trial registry, and VIP Chinese Science from inception to June 2025 to identify randomized controlled trials (RCTs) comparing bloodletting therapy vs. pharmacotherapy in acute HZ (≤10 days post-eruption). Primary outcomes included Clinical efficacy rate, Visual Analog Scale (VAS), Skin lesion presentation, Incidence of PHN. Risk of bias was assessed using Cochrane RoB 2.0. Data were pooled via appropriate statistical methods (RevMan 5.4). PROSPERO registration: CRD420251110060. Results: A total of 16 RCTs involving 1283 patients were included. Meta-analysis demonstrated that bloodletting therapy significantly improved clinical efficacy versus pharmacotherapy (OR=4.51, 95%CI [2.89,7.04], P<0.00001). Furthermore, BLT achieved superior pain reduction, evidenced by lower VAS scores (MD=-1.57, 95%CI [-1.93, -1.21], P<0.00001), and accelerated skin healing through shorter crust formation (MD=-1.58 days, 95%CI [-1.79, -1.38], P<0.00001) and scab detachment times (MD=-2.53 days, 95%CI [-3.82, -1.23], P=0.0001). Importantly, BLT reduced PHN incidence (OR=0.23, 95%CI [0.15,0.35], P<0.00001). Regarding safety, adverse events were comparable between groups (OR=0.66, 95%CI [0.31,1.38], P=0.26). Subgroup analyses suggested the superiority of fire needle techniques. Sensitivity analyses resolved high heterogeneity in some outcomes. Conclusion: Based on existing evidence predominantly, BLT may be associated with superior short-term outcomes in pain relief, skin lesion healing, and PHN prevention for acute herpes zoster compared to pharmacotherapy, and its safety profile appears acceptable. However, these findings must be interpreted with considerable caution due to the high risk of bias in the included studies and significant clinical heterogeneity. Moreover, the generalizability of the results is limited as all trials were conducted within a single region (China). Therefore, international, high-quality RCTs with standardized protocols and longer follow-ups are urgently needed to confirm these potential benefits and establish the long-term efficacy and safety of BLT.

Keywords: Herpes Zoster, Bloodletting Therapy, Systematic review, Meta-analysis, postherpeticneuralgia, Fire needle, Cupping

Received: 27 Jul 2025; Accepted: 28 Sep 2025.

Copyright: © 2025 Wu, Jiang, Wu, Jin, Wang, Guan and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Danhui Wu, 705274753@qq.com
Wei Shao, 852272089@qq.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.